Skip to main content
Clinical Trials/EUCTR2017-000687-16-IT
EUCTR2017-000687-16-IT
Active, Not Recruiting
Phase 1

ovel avenues for the rescue of intellectual disability in Down syndrome - Novel avenues for the rescue of intellectual disability in Down

AOU FEDERICO II0 sites20 target enrollmentJune 8, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
DOWN SYNDROME
Sponsor
AOU FEDERICO II
Enrollment
20
Status
Active, Not Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 8, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
AOU FEDERICO II

Eligibility Criteria

Inclusion Criteria

  • \- Subjects of either gender with Down syndrome aged between 5 and 10, extremes included;
  • \- Subjects who gave their consent to participate to the study by informed consent signature from parents or legal tutors before any data collection;
  • \- Subjects in euthyroidism (reference value: FT4\) with or without drug therapy;
  • \- Subjects, celiac or not, with negative values at screening for celiac disease (reference value: Antitransglutaminase antibodies IgA);
  • \- Subjects who never took fluoxetine previously.
  • \- Patients not treated with contraindicated concomitant therapies
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • \- Subjects aged less than 5 or more than 10;
  • \- Subjects with concomitant neurological diseases other than those expected for the Down syndrome phenotype;
  • \- Subjects with neuropsychiatric diseases: Depressive and Bipolar Disorders;
  • \- Subjects with major malformations requiring prolonged hospitalization;
  • \- Subjects with concomitant medical conditions such as: epilepsy, thyroid dysfunction (not in euthyroidism), diabetes, gastrointestinal,
  • hepatic or renal problems that may alter the absorption and the metabolism of the experimental drug; patients with bleeding disorders or history of bleeding disorders;
  • \- Subjects with long QT syndrome and/or familiarity of long QT syndrome;
  • \- Subjects with congenital cardiopathy, nocturnal apnea syndrome, pericarditis and myocarditis, hypertension or hypertensive crisis,
  • blood electrolytes alterations (in particular, potassium and calcium);
  • \- Subjects treated with controindicated concomitant therapies:

Outcomes

Primary Outcomes

Not specified

Similar Trials